Show Summary Details
Page of

The immunocompromised patient 

The immunocompromised patient
The immunocompromised patient
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 09 July 2020

Introduction 88

Common treatment points 88

Clinical assessment 88

Management 90

Acute respiratory disease is common in the immunocompromized population who include patients receiving cytotoxic chemotherapy or immunosuppressive therapy for non-malignant conditions (e.g. steroids, cyclophosphamide, azathioprine, methotrexate), recipients of organ transplants, patients with lymphoproliferative or myeloproliferative malignancies, and those with congenital or acquired immunodeficiencies. For a more detailed discussion see OHRM, Chapters 9 and 10....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.